TG-C is a non-surgical treatment cell-mediated gene therapy for osteoarthritis, which is the most common form of arthritis. A first-in-class cell and gene therapy, TG-C targets knee osteoarthritis through a single intra-articular injection.
Grade 3 knee osteoarthritis
LEDAGA® (chlormethine) gel is an alkylating drug indicated for the topical treatment of MF-CTCL in adult patients. LEDAGA® is a gel which is applied topically once a day. The drug has been approved by the European Commission (for the treatment of MF-CTCL in adult patients). Since June 2019, LEDAGA® is commercialized in more than 30 countries including Europe, Canada, Latin America.
Topical treatment of MF-CTCL
ANAMORELIN is a novel once-daily, orally active ghrelin receptor agonist indicated for the treatment of cancer cachexia in patients suffering from malignant tumors of non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer or colorectal cancer. Cancer cachexia is a complex metabolic disorder syndrome, characterized by decreased body weight (especially decreased muscle mass) and anorexia associated with cancer. It has been well documented that cancer cachexia causes a significant impact on patients’ quality of life (QOL) and prognosis.